Overview of Alzheimers Research Roberto Fernandez MD, MPH,

Overview of Alzheimers Research Roberto Fernandez MD, MPH,

Overview of Alzheimers Research Roberto Fernandez MD, MPH, PhD Medical Director The Pat Summitt Clinic Brain and Spine Institute University of Tennessee Medical Center 1 Overview

Normal brain structure and function Alzheimers pathology - What we know Alzheimers pathology - What we don't know The scope of research Clinical Trials in Alzheimers disease Clinical research at the Pat Summitt Clinic Brain Function Motor function Spoken language

Attention Planning Making Choices Suppression of unwanted behaviors Sensation Visuospatial function Integration of different Sensory systems Primary visual processing

Language comprehension Visual recognition Auditory processing Memory Behavior 3 Normal Brain Structure and Function Image: http://www.nia.nih.gov Image: www.martinos.org/neurorecovery/images/tracts.png 4

Alzheimers Pathology. What we know Not all brain regions are affected equally or at the same time Some areas are more vulnerable Hallmark changes are first seen in medial temporal lobes

Images: www.alz.org 5 Beta Amyloid Plaques Image: https://commons.wikimedia.org/ Image: wiki.brown.edu

Amyloid is a naturally occurring protein Formed from by cleavage of amyloid precursor protein Beta-amyloid has tendency to aggregate forming plaques Plaques formation is potentially toxic to neurons 6 Tau and Neurofibrillary Tangles Normal tau protein changes configuration and forms clumps, called neurofibrillary tangles, cause cell dysfunction and eventually cell death. 7 Loss of function and disease progression

X X X Loss of connections among brain cells and functional networks result in loss of function (memory, language, etc) and may contribute to spread of disease and cause further injury. 8 Disease Progression Progression of disease leads to

inflammation, cell injury, cell death and brain atrophy. Images: www.alz.org 9 Alzheimers Pathology: What We Don't Know What causes the changes in amyloid and tau Why individuals with amyloid burden may not develop AD Why are some parts of the brain more vulnerable than

others Why are there different variants of disease How does disease spread across brain regions What is the relationship with aging Whats the role of loss of connections between brain regions 10 The Scope of Biomedical Research Basic Research Molecular Animal Models Human subjects

Images: http: npr.org Images: http://www.lpzoo.org/ The Scope of Biomedical Research Symptomatic Drug Trials Clinical Research Disease Modifying Epidemiology

Preventive Genetics Imaging/EEG Diagnostics Labs Other Interventions

Cognitive 12 Clinical Trials Clinical Trials A clinical research study is a scientific investigation designed to answer important questions about a specific intervention: Is it safe?

Does it work? Which dose works best? What are the side effects? 13 Clinical Trials Progression of Clinical Trials Phase I: Tests new drug or treatment in a small group of people to assess safety, safe dose range, and identify side effects Phase II: Tests safety and/or efficacy Phase III: Studies conducted in large groups to confirm effectiveness, monitor side effects and compare to

standard treatments 14 Clinical Trials Study Design Most trials are double blinded placebo-control trials Some may be open label Some have open label extensions after completion of blinded portion of the study Most have strict inclusion criteria Duration, frequency of visits and procedures (e.g. tests) varies depending on protocol Close monitoring for possible side effects

15 Clinical Trials When considering a clinical trial: Know your rights Do not feel obligated to participate

You can decide to stop at any time Make sure you inform yourself about research evidence backing the study It is OK to ask for second opinion Make sure you review and understand the informed consent. Dont be afraid to ask questions Make sure trial is conducted by a reputable institution All research with human subjects must be conducted by entities who have an Institutional Review Board (IRB) Be aware that food supplements and natural products may not be regulated in the same manner as therapeutic drugs, but may still have risks and possible side effects 16

Current Therapeutic Research in Alzheimers There are currently no approved medications that can cure, slow down or revert Alzheimers Approved medications are intended to treat symptoms and may provide temporary improvement Experimental drugs target know mechanism of disease through different approaches: Beta-amyloid: Antibodies that help clear plaques, prevent aggregation or block enzymes involved in amyloid formation Neurofibrillary tangles: Vaccine that stimulates the bodys immune system to attack an abnormal form of tau protein that destabilizes the structure of neurons Inflammatory response: Drugs that can modulate inflammation

Neuronal network dysregulation: Anti-epileptic drugs to modulate possible hyperexcitability of brain cells Neurotransmitter function 17 Monoclonal Antibodies Selective for aggregated betaamyloid Bind to amyloid plaques Signal to immune cells that then recognize plaque and remove it Images: www.alz.org

18 Clinical research at the Pat Summitt Clinic ENGAGE Clinical Trial Study evaluating the efficacy and safety of an investigational drug in people experiencing symptoms of early Alzheimers disease. It is intended for preclinical Alzheimers, also known as mild cognitive impairment Study drug is aducanumab, a monoclonal antibody Prior studies showed statistically significant reduction in plaque and slowing of cognitive decline Aim to determine whether the investigational drug can remove the plaques and have an effect on the slowing of the progression of

the condition Infrequent but potentially serious adverse events have been associated with this medication. These include brain swelling and 19 brain bleeds. ENGAGE Clinical Trial Approximately 1350 people with symptoms of early Alzheimers disease will take part in this study around the world. Two phases: a placebo-controlled phase, and an optional long-term extension phase. Placebo-Control phase: two-in-three chance of receiving investigational drug. This phase lasts 2 years Long-Term phase: All participants will receive the drug for 2 years

Participants who meet eligible requirements will visit the clinic once or twice per month During placebo- controlled phase, participants will receive either the investigational drug or placebo every 4 weeks for approximately 18 months (1.5 years). 20 You may qualify for the study if: You are 5085 years of age You are experiencing symptoms that might be related to early Alzheimers disease, such as problems with memory or thinking clearly You have someone who can be your study partner (accompany you to certain appointments and provide

information about your health). 21 Clinical Research at the Pat Summitt Clinic Visuospatial Impairments in Alzheimers Disease (AD) Up to 1/3 of AD begins with visuospatial symptoms

Associated with posterior cortical atrophy Disabling because it undermines independent living 22 Brain Areas for Visuospatial Orientation and Alzheimers disease

Dorsal Where? Ventral What? 23 Optic Flow The visual motion seen during self movement Alzheimers can impair optic flow perception, leading to disorientation 24

Brain responses to it can be measured with EEG 25 Brainwaves evoked by optic flow can differentiate early stage Alzheimers from normal aging. 26 Optic flow responses are associated with poor driving performance and

atrophy of specific brain regions that are affected in Alzheimers 27 Current Research To establish the parameters of OF-ERP components that will reliably differentiate normal aging from Alzheimers for early diagnosis and monitoring of disease progression Elucidate mechanism of Alzheimers disease that are poorly understood

Evaluate optic flow brain responses as objective predictors of driving capacity 28 Thank You

Recently Viewed Presentations

  • The Essential Elements of Public Speaking Joseph A.

    The Essential Elements of Public Speaking Joseph A.

    Persuading Your Audience Use Emotional Appeals Self-Actualization Needs Self-Esteem Needs Belonging/Love Needs Safety Needs Physiological Needs Appealing to Hierarchy of Needs Maslow's Hierarchy of Needs Persuading Your Audience Use Credibility Appeals Audience Sees You as Believable Based On Competence Character...
  • Magnetism Magnetic Fields Magnetic Forces Certain objects and

    Magnetism Magnetic Fields Magnetic Forces Certain objects and

    Torque is proportional to separation of forces F F W Wsin Edge-on view of Loop B Torque and Energy for a Loop R I Define A to be a vector perpendicular to the loop with area A and in the...
  • America Becomes A Colonial Power

    America Becomes A Colonial Power

    The Treaty of Paris: 1898. Ends S-A War. Cuba was freed from Spanish rule. Spain gave up Puerto Rico and the island of. Guam. The U. S. paid Spain. $20 mil. for the. Philippines. The U. S. becomes. an imperial...
  • Customs vary throughout Mexico Most celebrations include: Decoration

    Customs vary throughout Mexico Most celebrations include: Decoration

    *Altars have decorations: papel picado, candles, flowers, photographs of the departed, candy skulls with the name of the deceased *Altars have foods and drinks: bottles of beer or tequila, cups of atole (a sweet drink made of milk, sugar, and...
  • Diapositive 1

    Diapositive 1

    The detection instrument for the quantitative determinationvaryfrom a single Petridish to different dilutions and MPN system of diverse complexity. Intrinsicvariablity of microbiologicaldeterminations ... Every technical step of the method adds to the total variability of the measurement: Sub ...
  • Landscape Disturbance  Disturbance defined as:  Relatively discrete event

    Landscape Disturbance Disturbance defined as: Relatively discrete event

    What types exist? Can they be reintroduced? Disturbance Regimes in Michigan Mack Lake Fire, 1980 First 6 hours 1 human life 44 homes 20,000 A After 30 hours, fire contained within 24,000 A area Are disturbance regimes evident in Michigan...
  • Title


    Significant GlidePath Results. 66% of employees substantially "bought down" on the exchange. 62% . of employees took the GlidePath Decision Support survey. 79% . of members believe their enrollment experience is as good as or better than last year
  • Packet Switching (basics) Crossbar scheduling: Take-a-ticket  HOL Probability

    Packet Switching (basics) Crossbar scheduling: Take-a-ticket HOL Probability

    Times New Roman Arial Calibri Default Design Packet Switching (basics) Slide 2 Slide 3 Crossbar scheduling: "Take-a-ticket" HOL Probability that none of the N input ports chooses a given output port is (1-1/N)N ≈ 37% So, max throughput of this...